Automated Planning for Bias-Free Validation of Discrete Proton Arc Therapy for Oropharyngeal Cancer [0.03%]
用于口咽癌离散质子弧治疗无偏验证的自动计划研究
Wens Kong,Merle Huiskes,Steven J M Habraken et al.
Wens Kong et al.
Purpose: To systematically compare fully automated planning for 36-field discrete proton arc therapy (36PAT) with: (1) intensity-modulated proton therapy (IMPT) with 4- and 6-field clinical beam-angle class solutions (4CS...
Connecting Visual Perception With Proton Therapy-Induced Optic Damage Using Archetypal Analysis [0.03%]
利用原型分析连接视觉感知与质子治疗引起的视神经损伤
Thao-Nguyen Pham,Thibaud Mathis,Nathan Azemar et al.
Thao-Nguyen Pham et al.
Purpose: Radiotherapy can lead to radiation-induced optic neuropathy, with vision loss and visual field deficits related to localized damage to the optic pathways. Accurately quantifying visual field deficits and establis...
"Hadrontherapy for Life" Symposium, Caen, March 10/11, 2025-Strategy for the Future-Pancreatic Cancer [0.03%]
“Hadrontherapy for Life”国际研讨会——卡昂2025年3月10/11日大会：未来策略——胰腺癌治療
Jean-Louis Habrand,Siamak Haghdoost,Semi B Harrabi et al.
Jean-Louis Habrand et al.
The symposium "Hadrontherapy for Life," held in Caen, on February 10 and 11, 2025, brought together over 100 international experts of heavy ions particle therapy. Clinical aspects of current indications and future strategies were discussed....
Feasibility and efficacy of hypofractionated proton reirradiation for recurrent lung cancer [0.03%]
超分割质子再程放疗治疗复发性肺癌的可行性和有效性评估
Jerome M Karp,Kara M Banson,Oren Cahlon et al.
Jerome M Karp et al.
Purpose: The goal of this study is to report the feasibility and outcomes of hypofractionated proton reirradiation in patients with recurrent thoracic tumors. ...
"Hadrontherapy for Life" Symposium, Caen, March 10/11, 2025-Strategy for the Future-Pediatric Tumors [0.03%]
“hadrontherapy for life”国际研讨会——儿科肿瘤的未来策略_caen，2025年3月10-11日
Jean-Louis Habrand,Semi B Harrabi,Shigeru Yamada et al.
Jean-Louis Habrand et al.
The symposium "Hadrontherapy for life," held in Caen, on March 10 and 11, 2025, brought together over 100 international experts of heavy ions particle therapy. Clinical aspects of current indications and future strategies were discussed. If...
Corrigendum to "Validation of Derived Relative Stopping Power Using Fast Switch KV Dual Energy CT for Proton Planning" [Int J Part Ther Vol. 15 (2025) Page 3] [0.03%]
“基于快切换单球管双能CT验证质子治疗计划中的相对停止功率”一文勘误(第15卷(2025年)第3页)
Hazel Wang,Yanling Qu,Yang Li et al.
Hazel Wang et al.
[This corrects the article DOI: 10.1016/j.ijpt.2024.100646.]. © 2025 Published by Elsevier B.V. on behalf of Particle Therapy Co-operative Group.
Relative Biological Effectiveness-Clinical Practice at US Proton Therapy Centers [0.03%]
美国质子治疗中心的相对生物效应-临床实践
Armin Lühr,Radhe Mohan,Anita Mahajan et al.
Armin Lühr et al.
Purpose: Proton therapy, with its high conformality and superior dose distribution, is becoming an increasingly prevalent modality in radiation oncology. Although a generic relative biological effectiveness (RBE) value of...
In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma [0.03%]
基于光子和质子的立体定向体放射治疗初期肾细胞癌的剂量递增的最大峰值剂量的仿真比较
Sherif G Shaaban,Hao Chen,Anh Tran et al.
Sherif G Shaaban et al.
Purpose: Photon based Stereotactic Body Radiotherapy (PH-SBRT) has emerged as a promising option for treatment of primary renal cell carcinoma (RCC), however is associated with decrements in long-term kidney function and ...
Benchmarking Modern Day Pencil Beam Scanning Proton Therapy Treatment Times: Insights From Real Time Location Service Treatment Time Data [0.03%]
现代铅笔束扫描质子治疗时间基准：来自实时定位服务治疗时间数据的见解
Kristen McConnell,Andrew Wroe,Maria Valladares et al.
Kristen McConnell et al.
Purpose: Collecting consistent and accurate treatment time data is challenging, particularly when relying on manual records or predictive models. Our center uses a Real-Time Location System (RTLS), which provides precise,...
Irini Yacoub,Achraf Shamseddine,Daniel Kallini et al.
Irini Yacoub et al.
Purpose/objectives: Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy with a prolonged but infiltrative course, marked by perineural invasion and high risk of local recurrence and distant metastases...